Boston Scientific's drug-coated stent gets FDA approval

The medical device maker intends to launch Eluvia in the fourth quarter, Jeff Mirviss, president of Boston Scientific's Peripheral Interventions division, told Reuters. Eluvia, approved in Europe since 2016, targets the 8.5 million people in the United States who suffer from peripheral artery disease (PAD), a painful condition caused by plaque buildup in the arteries of the limbs. Eluvia is a tiny wire mesh scaffolding with a drug-polymer coating that releases paclitaxel, an existing chemotherapy drug, for about a year to prevent reclogging.

from Yahoo News - Latest News & Headlines https://ift.tt/2OJIOx2